Nonpeptide Ligands for Peptidergic G Protein-Coupled Receptors

被引:0
作者
Geary, Timothy G. [1 ]
机构
[1] McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ H9X 3V9, Canada
来源
NEUROPEPTIDE SYSTEMS AS TARGETS FOR PARASITE AND PEST CONTROL | 2010年 / 692卷
关键词
TYPE-2; DIABETES-MELLITUS; DRUG DISCOVERY; OPIOID RECEPTORS; SUBSTANCE-P; CHOLECYSTOKININ ANTAGONISTS; SACCHAROMYCES-CEREVISIAE; NEUROKININ-1; RECEPTOR; SPECIES SELECTIVITY; PHYLUM NEMATODA; MOLECULAR-BASIS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Neuropeptides play essential roles in many physiological systems in vertebrates and invertebrates. Peptides per se are difficult to use as therapeutic agents, as they are generally very unstable in biological fluid environments and cross biological membranes poorly. Recognition that nonpeptide ligands for peptide receptors have clinical utility came from the discovery that opiates (such as morphine) act by binding to G protein-coupled receptors (GPCRs) for which the endogenous ligands are a family of neuropeptides (enkephalins and endorphins). Basic research has revealed a very large number of distinct neuropeptides that influence virtually every aspect of mammalian physiology and considerable effort has been expended in the pursuit of new drugs that act through peptidergic signaling systems. Although useful drugs have been found to affect various aspects of neuropeptide biology, most work has been devoted to the discovery of nonpeptide ligands that act as agonists or antagonists at peptidergic GPCRs. Similar opportunities are apparent for the discovery of nonpeptide ligands that act on invertebrate GPCRs. A consideration of the knowledge gained from the process as conducted for mammalian peptidergic systems can inform and illuminate promising strategies for the discovery of new drugs for the treatment and control of pests and parasites.
引用
收藏
页码:10 / 26
页数:17
相关论文
共 72 条
[21]   DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST [J].
GETHER, U ;
JOHANSEN, TE ;
SNIDER, RM ;
LOWE, JA ;
NAKANISHI, S ;
SCHWARTZ, TW .
NATURE, 1993, 362 (6418) :345-348
[22]   PEPTIDOMIMETICS FOR RECEPTOR LIGANDS DISCOVERY, DEVELOPMENT, AND MEDICAL PERSPECTIVES [J].
GIANNIS, A .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1993, 32 (09) :1244-1267
[23]   STEREOSPECIFIC AND NONSPECIFIC INTERACTIONS OF MORPHINE CONGENER LEVORPHANOL IN SUBCELLULAR FRACTIONS OF MOUSE BRAIN [J].
GOLDSTEIN, A ;
LOWNEY, LI ;
PAL, BK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1971, 68 (08) :1742-+
[24]   Nematode neuropeptide receptors and their development as anthelmintic screens [J].
Greenwood, K ;
Williams, T ;
Greary, T .
PARASITOLOGY, 2005, 131 :S169-S177
[25]   Peptide-binding G protein-coupled receptors: New opportunities for drug design [J].
Gurrath, M .
CURRENT MEDICINAL CHEMISTRY, 2001, 8 (13) :1605-1648
[26]   Drosophila uses two distinct neuropeptide amidating enzymes, dPAL1 and dPAL2 [J].
Han, M ;
Park, D ;
Vanderzalm, PJ ;
Mains, RE ;
Eipper, BA ;
Taghert, PH .
JOURNAL OF NEUROCHEMISTRY, 2004, 90 (01) :129-141
[27]   Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists [J].
Hansen, K. B. ;
Knop, F. K. ;
Holst, J. J. ;
Vilsboll, T. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) :1154-1160
[28]  
HAWKING F, 1963, EXPT CHEMOTHERAPY, P1
[29]   Cholecystokinin antagonists: Pharmacological and therapeutic potential [J].
Herranz, R .
MEDICINAL RESEARCH REVIEWS, 2003, 23 (05) :559-605
[30]   Neuropeptides -: an overview [J].
Hökfelt, T ;
Broberger, C ;
Xu, ZQD ;
Sergeyev, V ;
Ubink, R ;
Diez, M .
NEUROPHARMACOLOGY, 2000, 39 (08) :1337-1356